DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average rating of “Moderate Buy” by the twenty-four ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $86.50.

Several equities analysts have recently weighed in on the stock. Leerink Partners reiterated an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a research note on Tuesday, December 16th. Mizuho increased their price objective on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, February 13th. Barclays reiterated an “underweight” rating and issued a $72.00 price objective (up from $71.00) on shares of DexCom in a research note on Friday, February 13th. Finally, Wells Fargo & Company decreased their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $65.68 on Friday. The firm’s 50 day moving average price is $68.38 and its 200-day moving average price is $66.94. DexCom has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $25.28 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 1.28 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the business earned $0.45 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that DexCom will post 2.03 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00. Following the sale, the executive vice president owned 112,904 shares in the company, valued at approximately $7,321,824.40. This trade represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Reflection Asset Management bought a new stake in DexCom during the 4th quarter worth approximately $25,000. Twin Peaks Wealth Advisors LLC bought a new stake in DexCom during the 2nd quarter worth approximately $26,000. SJS Investment Consulting Inc. raised its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in DexCom during the 3rd quarter worth approximately $29,000. Finally, CVA Family Office LLC raised its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.